Complete financial analysis of Nektar Therapeutics (NKTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nektar Therapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Carefree Group, Inc. (CRFU) Income Statement Analysis – Financial Results
- Torrent Pharmaceuticals Limited (TORNTPHARM.BO) Income Statement Analysis – Financial Results
- Costco Wholesale Corporation (COST.BA) Income Statement Analysis – Financial Results
- Xtera Communications, Inc. (XCOMQ) Income Statement Analysis – Financial Results
- STEF SA (STF.PA) Income Statement Analysis – Financial Results
Nektar Therapeutics (NKTR)
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.12M | 92.06M | 101.91M | 152.92M | 114.62M | 1.19B | 307.71M | 165.44M | 230.78M | 200.71M | 148.92M | 81.19M | 71.48M | 159.04M | 71.93M | 90.19M | 273.03M | 217.72M | 126.28M | 114.27M | 106.26M | 94.85M | 77.47M | 51.63M | 41.36M | 21.80M | 16.25M | 6.90M | 3.40M | 1.70M |
| Cost of Revenue | 36.64M | 21.64M | 24.90M | 19.48M | 21.37M | 24.41M | 30.55M | 30.22M | 34.10M | 28.53M | 38.51M | 30.43M | 21.89M | 25.67M | 30.95M | 35.04M | 147.52M | 118.09M | 36.00M | 19.80M | 14.68M | 7.02M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.10M | -500.00K |
| Gross Profit | 53.48M | 70.42M | 77.01M | 133.44M | 93.24M | 1.17B | 277.16M | 135.22M | 196.68M | 172.17M | 110.41M | 50.76M | 49.59M | 133.37M | 40.98M | 55.15M | 125.51M | 99.63M | 90.28M | 94.47M | 91.58M | 87.83M | 73.30M | 51.63M | 41.36M | 21.80M | 16.25M | 8.10M | 4.50M | 2.20M |
| Gross Profit Ratio | 59.34% | 76.50% | 75.57% | 87.26% | 81.35% | 97.95% | 90.07% | 81.74% | 85.22% | 85.78% | 74.14% | 62.52% | 69.37% | 83.86% | 56.98% | 61.15% | 45.97% | 45.76% | 71.49% | 82.67% | 86.19% | 92.60% | 94.62% | 100.00% | 100.00% | 100.00% | 100.00% | 117.39% | 132.35% | 129.41% |
| Research & Development | 114.16M | 218.32M | 400.27M | 408.68M | 434.57M | 399.54M | 268.46M | 203.80M | 182.79M | 147.73M | 190.01M | 148.68M | 126.77M | 108.07M | 95.11M | 154.42M | 153.58M | 149.38M | 151.66M | 133.52M | 131.53M | 157.38M | 139.65M | 101.54M | 64.08M | 35.40M | 23.65M | 14.40M | 9.00M | 0.00 |
| General & Administrative | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 3.20M | 7.40M |
| Other Expenses | 0.00 | -116.00K | -24.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 392.00K | 983.00K | 0.00 | 0.00 | 0.00 | -68.11M | -48.25M | 31.16M | 69.55M | 3.92M | 4.22M | 4.51M | 25.49M | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 4.30M | 7.90M |
| Operating Expenses | 190.90M | 310.66M | 523.11M | 513.36M | 533.28M | 480.98M | 320.83M | 248.08M | 226.05M | 188.66M | 230.54M | 190.29M | 173.53M | 149.05M | 136.12M | 137.80M | 161.66M | 258.86M | 265.06M | 168.41M | 157.76M | 187.91M | 184.00M | 115.48M | 71.95M | 43.79M | 29.97M | 19.60M | 13.30M | 7.90M |
| Cost & Expenses | 227.55M | 332.29M | 548.01M | 532.84M | 554.65M | 505.39M | 351.37M | 278.29M | 260.16M | 217.19M | 269.05M | 220.72M | 195.42M | 174.72M | 167.06M | 172.84M | 309.18M | 376.95M | 301.05M | 188.21M | 172.44M | 194.93M | 188.17M | 115.48M | 71.95M | 43.79M | 29.97M | 18.40M | 12.20M | 7.40M |
| Interest Income | 19.01M | 6.67M | 2.57M | 18.28M | 46.34M | 37.57M | 4.52M | 2.39M | 1.68M | 814.00K | 732.00K | 2.32M | 2.24M | 1.55M | 3.69M | 12.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.33M | 28.91M | 47.31M | 37.12M | 46.35M | 42.78M | 40.95M | 42.18M | 38.90M | 38.76M | 40.76M | 33.55M | 10.22M | 11.17M | 12.18M | 15.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.82M | 12.20M | 13.00M | 12.50M | 11.00M | 8.80M | 12.60M | 13.20M | 12.86M | 12.93M | 14.28M | 14.51M | 14.95M | 16.55M | 14.88M | 22.49M | 28.15M | 32.64M | 26.23M | 19.19M | 18.42M | 18.97M | 40.39M | 10.12M | 7.25M | 3.60M | 2.44M | 1.20M | 1.10M | 500.00K |
| EBITDA | -243.11M | -323.87M | -462.97M | -394.33M | -382.70M | 734.30M | -42.52M | -97.27M | -29.37M | -2.74M | -106.01M | -124.10M | -107.79M | -9.33M | -75.72M | 2.54M | -7.12M | -125.72M | -147.07M | -54.76M | -47.77M | -81.11M | -70.32M | -53.72M | -23.34M | -18.39M | -11.29M | -10.30M | -7.70M | -5.20M |
| EBITDA Ratio | -269.75% | -239.57% | -445.31% | -227.22% | -332.01% | 61.71% | -7.93% | -57.49% | -6.43% | -1.37% | -70.33% | -149.92% | -149.33% | 1.52% | -106.44% | -197.91% | -21.36% | -46.66% | -58.44% | -40.07% | -75.27% | -84.47% | 103.45% | -22.74% | -32.52% | -84.39% | -69.46% | -172.46% | -264.71% | -341.18% |
| Operating Income | -137.43M | -240.24M | -446.10M | -379.92M | -440.04M | 687.93M | -59.64M | -112.86M | -29.37M | -16.49M | -120.13M | -141.20M | -123.94M | -28.26M | -95.13M | -82.65M | -36.15M | -159.23M | -182.63M | -73.94M | -66.19M | -100.08M | -256.96M | -66.14M | -40.48M | -21.99M | -13.72M | -11.50M | -8.80M | -5.70M |
| Operating Income Ratio | -152.49% | -260.97% | -437.76% | -248.45% | -383.92% | 57.65% | -19.38% | -68.22% | -12.73% | -8.21% | -80.67% | -173.91% | -173.39% | -17.77% | -132.25% | -91.65% | -13.24% | -73.14% | -144.63% | -64.71% | -62.29% | -105.52% | -331.70% | -128.10% | -97.89% | -100.89% | -84.46% | -166.67% | -258.82% | -335.29% |
| Total Other Income/Expenses | -138.83M | -124.75M | -77.18M | -64.03M | -19.00K | -5.21M | -36.43M | -39.79M | -51.30M | -37.94M | -39.64M | -30.25M | -9.02M | -8.80M | -7.64M | 47.51M | 4.70M | 5.30M | -2.62M | -28.11M | 19.67M | -7.39M | 6.96M | -31.26M | -9.89M | 0.00 | 0.00 | 1.60M | 1.30M | 600.00K |
| Income Before Tax | -276.26M | -364.98M | -523.28M | -443.95M | -440.05M | 682.73M | -96.08M | -152.65M | -80.67M | -54.43M | -159.77M | -171.45M | -132.96M | -37.06M | -102.77M | 35.14M | -31.45M | -153.93M | -185.25M | -102.05M | -46.51M | -107.47M | -250.01M | -97.40M | -50.37M | 0.00 | 0.00 | -9.90M | -7.50M | -5.10M |
| Income Before Tax Ratio | -306.54% | -396.48% | -513.49% | -290.32% | -383.93% | 57.21% | -31.22% | -92.27% | -34.96% | -27.12% | -107.28% | -211.17% | -186.01% | -23.30% | -142.88% | 38.97% | -11.52% | -70.70% | -146.70% | -89.31% | -43.77% | -113.31% | -322.72% | -188.66% | -121.80% | 0.00% | 0.00% | -143.48% | -220.59% | -300.00% |
| Income Tax Expense | -200.00K | 3.22M | 557.00K | 493.00K | 613.00K | 1.41M | 616.00K | 876.00K | 506.00K | -512.00K | 2.25M | 406.00K | 1.02M | 881.00K | -253.00K | -806.00K | 1.31M | 828.00K | -137.00K | -163.00K | 169.00K | 7.39M | 139.31M | 33.56M | 7.85M | -3.63M | -3.74M | -1.50M | -1.10M | -400.00K |
| Net Income | -276.06M | -368.20M | -523.84M | -444.44M | -440.67M | 681.31M | -96.69M | -153.52M | -81.18M | -53.92M | -162.01M | -171.86M | -133.98M | -37.94M | -102.52M | -34.34M | -32.76M | -154.76M | -185.11M | -101.89M | -46.68M | -107.47M | -250.01M | -97.40M | -38.45M | -18.36M | -9.98M | -10.00M | -7.70M | -5.30M |
| Net Income Ratio | -306.31% | -399.98% | -514.03% | -290.65% | -384.47% | 57.09% | -31.42% | -92.80% | -35.17% | -26.86% | -108.79% | -211.67% | -187.43% | -23.85% | -142.52% | -38.07% | -12.00% | -71.08% | -146.59% | -89.16% | -43.93% | -113.31% | -322.72% | -188.66% | -92.96% | -84.22% | -61.44% | -144.93% | -226.47% | -311.76% |
| EPS | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| EPS Diluted | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.57M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
| Weighted Avg Shares Out (Dil) | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.60M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
Best penny stocks to buy? Biotech penny stocks are heating up & these 4 might be worth watching now.
PureTech Health confirms ‘possible combination' with Nektar Therapeutics
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ:NKTR), Inc. Responding to press speculation, PureTech said it has exchanged indicative, non-binding proposals with Nektar Therapeutics regarding a possible...
Nektar.ai exits stealth mode to plug CRM data leakages
A lot of important data gets lost along the sales pipeline because sales teams use multiple tools, including email, Zoom and WhatsApp, to talk with buyers. Nektar.
Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive...
How to Find Penny Stocks to Buy in Summer 2022
Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What to Know About Buying Penny Stocks on May 11th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 11th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
Nektar Therapeutics (NASDAQ: NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team. Dimitry Nuyten, Nektar's Chief Medical Officer, will step down from his.
Nektar Therapeutics Will Cut 70% of Its Staff After Trial Failure
The biotech Nektar Therapeutics aims to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers Squibb.
Source: https://incomestatements.info
Category: Stock Reports